These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 27241473)

  • 1. Rational design of a protein that binds integrin αvβ3 outside the ligand binding site.
    Turaga RC; Yin L; Yang JJ; Lee H; Ivanov I; Yan C; Yang H; Grossniklaus HE; Wang S; Ma C; Sun L; Liu ZR
    Nat Commun; 2016 May; 7():11675. PubMed ID: 27241473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneously targeting cancer-associated fibroblasts and angiogenic vessel as a treatment for TNBC.
    Sharma M; Turaga RC; Yuan Y; Satyanarayana G; Mishra F; Bian Z; Liu W; Sun L; Yang J; Liu ZR
    J Exp Med; 2021 Apr; 218(4):. PubMed ID: 33561195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of Cancer-Associated Fibrotic Stroma by An Integrin α
    Turaga RC; Sharma M; Mishra F; Krasinskas A; Yuan Y; Yang JJ; Wang S; Liu C; Li S; Liu ZR
    Cell Mol Gastroenterol Hepatol; 2021; 11(1):161-179. PubMed ID: 32810598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrin αvβ3-targeted dynamic contrast-enhanced magnetic resonance imaging using a gadolinium-loaded polyethylene gycol-dendrimer-cyclic RGD conjugate to evaluate tumor angiogenesis and to assess early antiangiogenic treatment response in a mouse xenograft tumor model.
    Chen WT; Shih TT; Chen RC; Tu SY; Hsieh WY; Yang PC
    Mol Imaging; 2012; 11(4):286-300. PubMed ID: 22954145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of tumor angiogenesis by fastatin, the fourth FAS1 domain of betaig-h3, via alphavbeta3 integrin.
    Nam JO; Jeong HW; Lee BH; Park RW; Kim IS
    Cancer Res; 2005 May; 65(10):4153-61. PubMed ID: 15899806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular profiling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects.
    Palmowski M; Huppert J; Ladewig G; Hauff P; Reinhardt M; Mueller MM; Woenne EC; Jenne JW; Maurer M; Kauffmann GW; Semmler W; Kiessling F
    Mol Cancer Ther; 2008 Jan; 7(1):101-9. PubMed ID: 18202013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers.
    Camorani S; Crescenzi E; Gramanzini M; Fedele M; Zannetti A; Cerchia L
    Sci Rep; 2017 Apr; 7():46659. PubMed ID: 28425453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity.
    Eikesdal HP; Sugimoto H; Birrane G; Maeshima Y; Cooke VG; Kieran M; Kalluri R
    Proc Natl Acad Sci U S A; 2008 Sep; 105(39):15040-5. PubMed ID: 18818312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumor growth of human lung cancer cells in mice.
    Cui R; Takahashi F; Ohashi R; Gu T; Yoshioka M; Nishio K; Ohe Y; Tominaga S; Takagi Y; Sasaki S; Fukuchi Y; Takahashi K
    Lung Cancer; 2007 Sep; 57(3):302-10. PubMed ID: 17482311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of the antiangiogenic activity of interleukin-12 by peptide targeted delivery of the cytokine to alphavbeta3 integrin.
    Dickerson EB; Akhtar N; Steinberg H; Wang ZY; Lindstrom MJ; Padilla ML; Auerbach R; Helfand SC
    Mol Cancer Res; 2004 Dec; 2(12):663-73. PubMed ID: 15634755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple FAS1 domains and the RGD motif of TGFBI act cooperatively to bind αvβ3 integrin, leading to anti-angiogenic and anti-tumor effects.
    Son HN; Nam JO; Kim S; Kim IS
    Biochim Biophys Acta; 2013 Oct; 1833(10):2378-88. PubMed ID: 23792174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficiency of recombinant human TNF in human cancer therapy.
    Lejeune FJ; Liénard D; Matter M; Rüegg C
    Cancer Immun; 2006 Mar; 6():6. PubMed ID: 16551058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FAS1 domain protein inhibits VEGF165-induced angiogenesis by targeting the interaction between VEGFR-2 and αvβ3 integrin.
    Nam JO; Son HN; Jun E; Cha K; Lee BH; Park RW; Kim IS
    Mol Cancer Res; 2012 Aug; 10(8):1010-20. PubMed ID: 22710795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does imaging αvβ3 integrin expression with PET detect changes in angiogenesis during bevacizumab therapy?
    Rylova SN; Barnucz E; Fani M; Braun F; Werner M; Lassmann S; Maecke HR; Weber WA
    J Nucl Med; 2014 Nov; 55(11):1878-84. PubMed ID: 25278514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of TAX2 peptide as a new unpredicted anti-cancer agent.
    Jeanne A; Sick E; Devy J; Floquet N; Belloy N; Theret L; Boulagnon-Rombi C; Diebold MD; Dauchez M; Martiny L; Schneider C; Dedieu S
    Oncotarget; 2015 Jul; 6(20):17981-8000. PubMed ID: 26046793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. alphavbeta3 Integrin-dependent antiangiogenic activity of resveratrol stereoisomers.
    Belleri M; Ribatti D; Savio M; Stivala LA; Forti L; Tanghetti E; Alessi P; Coltrini D; Bugatti A; Mitola S; Nicoli S; Vannini V; Presta M
    Mol Cancer Ther; 2008 Dec; 7(12):3761-70. PubMed ID: 19074851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid hormones and tetrac: new regulators of tumour stroma formation via integrin αvβ3.
    Schmohl KA; Müller AM; Wechselberger A; Rühland S; Salb N; Schwenk N; Heuer H; Carlsen J; Göke B; Nelson PJ; Spitzweg C
    Endocr Relat Cancer; 2015 Dec; 22(6):941-52. PubMed ID: 26307023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice.
    Reinmuth N; Liu W; Ahmad SA; Fan F; Stoeltzing O; Parikh AA; Bucana CD; Gallick GE; Nickols MA; Westlin WF; Ellis LM
    Cancer Res; 2003 May; 63(9):2079-87. PubMed ID: 12727823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
    Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
    Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting integrin αvβ3 by a rationally designed protein for chronic liver disease treatment.
    Turaga RC; Satyanarayana G; Sharma M; Yang JJ; Wang S; Liu C; Li S; Yang H; Grossniklaus H; Farris AB; Gracia-Sancho J; Liu ZR
    Commun Biol; 2021 Sep; 4(1):1087. PubMed ID: 34531529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.